Join to view full profile
5841 S. MARYLANDM/C 2115Chicago, IL 60637
Phone+1 773-702-7609
Fax+1 773-702-3163
Dr. Szmulewitz is on Doximity
As a Doximity member, you’ll join more than three million U.S. healthcare professionals—including 85+% of physicians, and 2/3 of all NPs and PAs—in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Education & Training
University of ChicagoFellowship, Hematology and Medical Oncology, 2006 - 2009
NYU Grossman School of MedicineResidency, Internal Medicine, 2003 - 2006
University of Chicago Division of the Biological Sciences The Pritzker School of MedicineClass of 2003
Certifications & Licensure
IL State Medical License 2006 - 2029
MI State Medical License 2026 - 2029
AZ State Medical License 2026 - 2028
FL State Medical License 2026 - 2028
MT State Medical License 2026 - 2028
IN State Medical License 2026 - 2027
WI State Medical License 2022 - 2023
American Board of Internal Medicine Medical Oncology- Join now to see all
Awards, Honors, & Recognition
- CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory - Core EMR, Epic Systems Corporation, 2013-2017
- CMS Meaningful Use Stage 2 Certification EpicCare Ambulatory 2014 Certified EHR Suite, Epic Systems Corporation, 2013-2017
- CMS Meaningful Use Stage 2 Certification EpicCare Inpatient 2014 Certified EHR Suite, Epic Systems Corporation, 2013-2017
Clinical Trials
Publications & Presentations
PubMed
- Recruitment strategies in the PROMISE Registry: Evaluating institutional outreach, direct-to-patient marketing, and community engagement approaches in a decentralized ...Channing J Paller, Ken Freitas, Natalie Macario, Christina Tran, Kelly Faville
Contemporary Clinical Trials Communications. 2026-10-01 - [Lu]Lu-PSMA-617 in patients with PSMA-positive metastatic androgen pathway modulator-naive/sensitive prostate cancer (PSMAddition): a phase 3 randomised, controlled tr...Scott T Tagawa, Oliver Sartor, Josep M Piulats, Fred Saad, Karim Fizazi
Lancet. 2026-08-06 - Radiochemistry and comparative in vitro assessment of PSMA-617 labeled with lead-212 (Pb), actinium-225 (Ac), and lutetium-177 (Lu).Abhijit Bera, Graham Ragland, Yuhan Zhang, Patricia G Madel, Jasmine B'Lanton
EJNMMI Radiopharmacy and Chemistry. 2026-05-20
Press Mentions
The Promises — and Challenges — of the FDA’s Real-Time Clinical Trial ModelJune 3rd, 2026- Benefits of PSMA-PET for High-risk/Advanced Prostate Cancer: Part 2August 26th, 2022
- Benefits of PSMA-PET for High-risk/Advanced Prostate Cancer: Part 1August 26th, 2022
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
